Unknown

Dataset Information

0

Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.


ABSTRACT: Platelet-derived growth factor receptor A is altered by amplification and/or mutation in diffuse intrinsic pontine glioma (DIPG). We explored in vitro on new DIPG models the efficacy of dasatinib, a multi-tyrosine kinase inhibitor targeting this receptor.Gene expression profiles were generated from 41 DIPGs biopsied at diagnosis and compared with the signature associated with sensitivity/resistance to dasatinib. A panel of 12 new DIPG cell lines were established from biopsy at diagnosis, serially passaged, and characterized by gene expression analyses. Effects of dasatinib (1-10 ?M) on proliferation, invasion, and cytotoxicity were determined on 4 of these cell lines using live-cell imaging and flow cytometry assays. Downstream signaling and receptor tyrosine kinases (RTKs) were assessed by western blot and phospho-RTK array. The effect of the combination with the c-Met inhibitor cabozantinib was studied on cellular growth and invasion analyzed by the Chou-Talaly method.DIPG primary tumors and cell lines exhibited the gene expression signature of sensitivity to dasatinib. Dasatinib reduced proliferation (half-maximal inhibitory concentration = 10-100 nM) and invasion (30%-60% reduction) at 100 nM in 4/4 cultures and induced apoptosis in 1 of 4 DIPG cell lines. Activity of downstream effectors of dasatinib targets including activin receptor 1 was strongly reduced. Since multiple RTKs were activated simultaneously in DIPG cell lines, including c-Met, which can be also amplified in DIPG, the benefit of the combination of dasatinib with cabozantinib was explored for its synergistic effects on proliferation and migration/invasion in these cell lines.Dasatinib exhibits antitumor effects in vitro that could be increased by the combination with another RTK inhibitor targeting c-Met.

SUBMITTER: Truffaux N 

PROVIDER: S-EPMC5654348 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.

Truffaux Nathalène N   Philippe Cathy C   Paulsson Janna J   Andreiuolo Felipe F   Guerrini-Rousseau Léa L   Cornilleau Gaétan G   Le Dret Ludivine L   Richon Catherine C   Lacroix Ludovic L   Puget Stéphanie S   Geoerger Birgit B   Vassal Gilles G   Östman Arne A   Grill Jacques J  

Neuro-oncology 20141221 7


<h4>Background</h4>Platelet-derived growth factor receptor A is altered by amplification and/or mutation in diffuse intrinsic pontine glioma (DIPG). We explored in vitro on new DIPG models the efficacy of dasatinib, a multi-tyrosine kinase inhibitor targeting this receptor.<h4>Methods</h4>Gene expression profiles were generated from 41 DIPGs biopsied at diagnosis and compared with the signature associated with sensitivity/resistance to dasatinib. A panel of 12 new DIPG cell lines were establishe  ...[more]

Similar Datasets

2014-03-31 | E-GEOD-50025 | biostudies-arrayexpress
2014-03-31 | GSE50025 | GEO
| S-EPMC8709907 | biostudies-literature
| S-EPMC5327462 | biostudies-literature
| S-EPMC5368268 | biostudies-literature
| S-EPMC5462626 | biostudies-literature
| S-EPMC6113938 | biostudies-other
| S-EPMC5566706 | biostudies-literature
| S-EPMC6025797 | biostudies-literature
| S-EPMC5327456 | biostudies-literature